Overview
Plain-language guide
Designed for research into Obesity. It remains investigational for these uses.
It copies or works with amylin, a hormone signal involved in fullness and how quickly food leaves the stomach.
Clinical mechanism
Selectively activates amylin receptors to affect satiety and energy intake.
Applications
Human evidence
Early or mid-stage human data exist, but confirmation, replication or long-term follow-up remains incomplete.
Tier 2Preclinical evidence
Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.
Regulatory status
Investigational. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.
Safety
Uncertain or Concerning
- Adverse effects vary by product and indication
- Contraindications and interactions require label review
Interactions
Review the current product label and indication-specific literature for pharmacologic and absorption interactions.
Treatment pattern
Treatment patterns are product-, indication- and clinician-specific; this educational profile does not provide dosing guidance.
Manufacturing and quality
Approved-product identity, formulation and quality controls must not be extrapolated to compounded or RUO copies.
Sponsor and development history
Eli Lilly and Company · Phase 2. Development programs and ownership can change; confirm current sponsor disclosures.
Sources
- 01Primary regulatory record
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 02Clinical trial registry
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
- 03Peer-reviewed literature
Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.
Gaps and unverified claims
- Long-term outcomes and real-world safety are not yet established.
- Current phase and catalysts require primary-source confirmation.
Last reviewed
August 5, 2026 · Reviewed